• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

根据RECIST标准，未分化大细胞食管腺癌对Irvalec（PM02734）产生完全且持续的客观反应：一例病例报告及文献综述

Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature.

作者信息

Salazar Ramón, Cuadra Carmen, Gil-Martín Marta, Vandermeeren Andrea, Alfaro Vicente, Coronado Cinthya

机构信息

Instituto Catalán de Oncología-IDIBELL, Barcelona, Spain.

出版信息

Case Rep Oncol. 2012 May;5(2):354-8. doi: 10.1159/000341104. Epub 2012 Jul 5.

DOI:10.1159/000341104
PMID:22807904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3398100/
Abstract

Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-fluorouracil, docetaxel and carboplatin/plitidepsin who received treatment with a novel antitumor agent, Irvalec (PM02734), as fourth line. The patient received treatment from July 2006 to July 2009, a total of 49 cycles, at a dose of 2.4 mg/m(2) as a 24-hour infusion every 3 weeks. He did not present severe complications or unplanned or cumulative toxicities. Complete and durable response according to RECIST was reported. He was alive at the last follow-up on March 2012.

摘要

未分化大细胞癌在食管癌中是一种罕见的类型，关于这种不常见组织学亚型的文献资料很少。我们报告一例58岁的白种男性患者，该患者先前接受过顺铂/5-氟尿嘧啶、多西他赛和卡铂/普利地肽素治疗，作为四线治疗接受了新型抗肿瘤药物Irvalec（PM02734）治疗。该患者从2006年7月至2009年7月接受治疗，共49个周期，剂量为2.4mg/m²，每3周进行一次24小时静脉输注。他未出现严重并发症或非计划性或累积性毒性反应。据报告，根据RECIST标准达到了完全且持久的缓解。在2012年3月的最后一次随访时他仍存活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e61/3398100/483a7e04e6b3/cro-0005-0354-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e61/3398100/0aeb1fdd567d/cro-0005-0354-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e61/3398100/483a7e04e6b3/cro-0005-0354-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e61/3398100/0aeb1fdd567d/cro-0005-0354-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e61/3398100/483a7e04e6b3/cro-0005-0354-g02.jpg

相似文献

1
Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature.根据RECIST标准，未分化大细胞食管腺癌对Irvalec（PM02734）产生完全且持续的客观反应：一例病例报告及文献综述
Case Rep Oncol. 2012 May;5(2):354-8. doi: 10.1159/000341104. Epub 2012 Jul 5.
2
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.术前使用紫杉醇、顺铂、5-氟尿嘧啶并联合放疗的强化综合治疗方案用于可切除食管癌的生存情况：一项I期报告
J Thorac Cardiovasc Surg. 2003 Oct;126(4):1168-73. doi: 10.1016/s0022-5223(03)00977-2.
3
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.对于局部晚期食管癌患者，与顺铂/紫杉醇联合治疗相比，新辅助放化疗联合顺铂/5-氟尿嘧啶可提高病理完全缓解率并改善生存率。
Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015.
4
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.紫杉醇、氟尿嘧啶和顺铂用于晚期食管癌患者的II期试验。
J Clin Oncol. 1998 May;16(5):1826-34. doi: 10.1200/JCO.1998.16.5.1826.
5
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.普利替肽素用于局部晚期或转移性非小细胞肺癌预处理患者的II期研究。
Lung Cancer. 2008 Jun;60(3):374-80. doi: 10.1016/j.lungcan.2007.10.019. Epub 2007 Dec 3.
6
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].基于铂类化合物联合5-氟尿嘧啶的DLF、CLF和DFM方案治疗晚期食管癌的临床评估
Ai Zheng. 2006 Aug;25(8):1029-34.
7
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.多西他赛联合奈达铂和5-氟尿嘧啶治疗晚期食管癌的II期试验。
Chin J Cancer. 2010 Mar;29(3):321-4. doi: 10.5732/cjc.009.10432.
8
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.多西他赛、顺铂和 5-氟尿嘧啶低剂量方案用于晚期胃腺癌一线治疗的疗效和安全性。
Med Oncol. 2010 Sep;27(3):680-4. doi: 10.1007/s12032-009-9268-y. Epub 2009 Jul 25.
9
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.多西他赛和顺铂化疗在氟尿嘧啶/顺铂预处理食管癌中的 II 期研究。
Am J Clin Oncol. 2010 Dec;33(6):624-8. doi: 10.1097/COC.0b013e3181bead92.
10
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.新辅助化疗后序贯同步放化疗治疗局部晚期鼻咽癌。
Chin J Cancer. 2010 May;29(5):551-5. doi: 10.5732/cjc.009.10518.

引用本文的文献

1
Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases.食管未分化癌：16例临床病理研究
Hum Pathol. 2015 Mar;46(3):366-75. doi: 10.1016/j.humpath.2014.11.021. Epub 2014 Dec 17.
2
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.艾力西得平（Irvalec®）联合卡铂或吉西他滨用于晚期恶性肿瘤患者的I期研究。
Invest New Drugs. 2014 Jun;32(3):500-9. doi: 10.1007/s10637-013-0060-7. Epub 2014 Jan 7.
3
Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

本文引用的文献

1
Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study.无法手术的食管癌患者接受化疗和/或放疗与自膨式金属支架置入的生存比较：一项病例对照研究。
BMC Cancer. 2012 Feb 15;12:70. doi: 10.1186/1471-2407-12-70.
2
Identification of esophageal cancer in the General Practice Research Database.在全科医学研究数据库中识别食管癌。
Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1159-67. doi: 10.1002/pds.2249. Epub 2011 Sep 16.
3
External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma.
缺氧通过抑制羟化作用和改变脂筏的结构降低依利司他滨的效率。
Mar Drugs. 2013 Dec 2;11(12):4858-75. doi: 10.3390/md11124858.
外照射放疗联合腔内近距离放疗治疗食管癌。
Radiother Oncol. 2012 Feb;102(2):303-8. doi: 10.1016/j.radonc.2011.07.021. Epub 2011 Aug 30.
4
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.基于多模式放化疗的多西紫杉醇治疗局部晚期食管或胃食管交界癌的 II 期研究的长期结果。
Med Oncol. 2011 Dec;28 Suppl 1:S152-61. doi: 10.1007/s12032-010-9658-1. Epub 2010 Aug 21.
5
Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up.食管癌：诊断、治疗及随访临床实践指南
Ann Oncol. 2010 May;21 Suppl 5:v46-9. doi: 10.1093/annonc/mdq163.
6
Esophageal cancer chemotherapy: recent advances.食管癌化疗：最新进展
Gastrointest Cancer Res. 2008 Mar;2(2):85-92.
7
Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention.食管癌患者与健康相关的生活质量：新辅助放化疗后手术干预的影响
J Thorac Cardiovasc Surg. 2009 Jan;137(1):36-42. doi: 10.1016/j.jtcvs.2008.09.049.
8
Undifferentiated carcinoma of the esophagus with rapid growth of lymph node. A case report and review of the literature.
Tumori. 2008 May-Jun;94(3):411-5. doi: 10.1177/030089160809400319.
9
Trends in esophageal cancer incidence by histology, United States, 1998-2003.1998 - 2003年美国按组织学分类的食管癌发病率趋势
Int J Cancer. 2008 Sep 15;123(6):1422-8. doi: 10.1002/ijc.23691.
10
A survey of oesophageal cancer: pathology, stage and clinical presentation.食管癌调查：病理、分期及临床表现
Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93. doi: 10.1111/j.1365-2036.2006.02782.x.